Das Medizinportal
Menü

Literatur:

Personalisierte Medizin beim Mammakarzinom – State of the Art

Henriette Slemeyer, Achim Rody, Cornelia Liedtke, Lübeck (S. 10-14)

 

  1. Deutscher Ethikrat, Personalisierte Medizin – der Patient als Nutznießer oder Opfer?,  2013
  2. Rody A et al, Zielgerichtete Therapie des HER2-positiven metastasierten Mammakarzinoms, CME Gynäkologie und Geburtshilfe, 2015:R1-R16
  3. Prat A et al, Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol. 2013 Jan 10;31(2):203-9. doi: 10.1200/JCO.2012.43.4134. Epub 2012 Dec 10.
  4. Nitz U. et al, Genexpressionstests bei Brustkrebs: Pro Dtsch Ärztebl 2014; 111(45)
  5. Harbeck N et al, Personalized treatment of early-stage breast cancer: present concepts and future directions. Cancer Treat Rev. 2010 Dec;36(8):584-94. doi: 10.1016/j.ctrv.2010.04.007. Epub 2010 Jun
  6. Sparano JA et al., Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2015 Nov 19;373(21):2005-14. doi: 10.1056/NEJMoa1510764. Epub 2015 Sep 27.
  7. Gluz O et al, West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment. J Clin Oncol. 2016 Jul 10;34(20):2341-9. doi: 10.1200/JCO.2015.63.5383. Epub 2016 Feb 29.
  8. Delahaye L et al, Performance characteristics of the MammaPrint® breast cancer diagnostic gene signature. Future Medicine,  November 2013 ,Vol. 10, No. 8, Pages 801-811 , DOI 10.2217/pme.13.88
  9. Dubsky P et al, The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. Br J Cancer. 2013 Dec 10;109(12):2959-64. doi: 10.1038/bjc.2013.671. Epub 2013 Oct 24.
  10. Filipits M et al, A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res. 2011 Sep 15;17(18):6012-20. doi: 10.1158/1078-0432.CCR-11-0926. Epub 2011 Aug 1.
  11. Parker JS et al., Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009 Mar 10;27(8):1160-7. doi: 10.1200/JCO.2008.18.1370. Epub 2009 Feb 9.
  12. NanoString technologies, Prosigna Kommentierter Patientenbericht, 2013
  13. www.femtelle.de/de/ (aufgerufen: 20.06.2016)
  14. Harbeck N et al, Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer. 2013 May; 49(8):1825-35. doi: 10.1016/j.ejca.2013.01.007. Epub 2013 Mar 13.
  15. Denkert C et al, Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010 Jan 1;28(1):105-13. doi: 10.1200/JCO.2009.23.7370. Epub 2009 Nov 16.
  16. Marmé F Immunotherapy in Breast Cancer. Oncol Res Treat. 2016;39(6):335-45. doi: 10.1159/000446340. Epub 2016 May 25.
  17. www.vfa.de/de/arzneimittel-forschung/datenbanken-zu-arzneimitteln/individualisierte-medizin.html (aufgerufen:10.06.2016)
  18. Hertz DL et al, One step at a time: CYP2D6 guided tamoxifen treatment awaits convincing evidence of clinical validity. Pharmacogenomics. 2016 Jun; 17(8):823-6. doi: 10.2217/pgs-2016-0059. Epub 2016 Jun 1.
  19. Yardley DA et al, Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013 Oct;30(10):870-84. doi: 10.1007/s12325-013-0060-1. Epub 2013 Oct 25.
  20. Swain SM et al, Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015 Feb 19;372(8):724-34. doi: 10.1056/NEJMoa1413513.
  21. Morikawa A, Peereboom DM, Smith QR, et al.: Clinical evidence for drug penetration of capecitabine and lapatinib uptake in resected brain metastases from women with breast cancer ASCO Annual Meeting Proceedings, Abstr 514. J Clin Oncol 30 (Suppl 18).
  22. Verma S et al, Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012 Nov 8; 367(19):1783-91. doi: 10.1056/NEJMoa1209124. Epub 2012 Oct 1.

Prädiktion des Therapieansprechens am Beispiel von Kopf-Hals-Tumoren

Gunnar Wichmann, Susanne Wiegand, Andreas Dietz; Leipzig (S. 20-23)

 

  1. Robert-Koch-Institut 2015, Krebs in Deutschland 2011/2012, 10. Ausgabe, www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2015/krebs_in_deutschland_2015.pdf
  2. Gatta G, Botta L, Sánchez MJ, Anderson LA, Pierannunzio D, Licitra L; EUROCARE Working Group. Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study. Eur J Cancer. 2015 Sep 6. pii: S0959-8049(15)00749-2. doi: 10.1016/j.ejca.2015.07.043. [Epub ahead of print]
  3. Dietz A, Kopf-Hals-Tumoren – Therapie des Larynx-/Hypopharynxkarzinoms unter besonderer Berücksichtigung des Larynxorganerhalts, 2. Auflage, Bremen: Uni-Med, 2010.
  4. Boehm A, Lindner F, Wichmann G, Bauer U, Wittekind C, Knoedler M, Lordick F, Dietzsch S, Scholz M, Kortmann R, Dietz A. Impact of indication-shift of primary and adjuvant chemo radiation in advanced laryngeal and hypopharyngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2015 Aug;272(8):2017-25. doi: 10.1007/s00405-014-3134-z. Epub 2014 Jun 25.
  5. American Society of Clinical Oncology, Pfister DG, Laurie SA, Weinstein GS, Mendenhall WM, Adelstein DJ, Ang KK, Clayman GL, Fisher SG, Forastiere AA, Harrison LB, Lefebvre JL, Leupold N, List MA, O'Malley BO, Patel S, Posner MR, Schwartz MA, Wolf GT. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol. 2006 Aug 1; 24(22):3693-704. Epub 2006 Jul 10. Review.
  6. Trotti A, Pajak TF, Gwede CK, Paulus R, Cooper J, Forastiere A, Ridge JA, Watkins-Bruner D, Garden AS, Ang KK, Curran W. TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol. 2007 Jul;8(7):613-24.
  7. Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, Forastiere A, Ang KK. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol. 2008 Jul 20;26(21):3582-9. doi: 10.1200/JCO.2007.14.8841. Epub 2008 Jun 16.
  8. Grover S, Swisher-McClure S, Mitra N, Li J, Cohen RB, Ahn PH, Lukens JN, Chalian AA, Weinstein GS, O'Malley BW Jr, Lin A. Total laryngectomy versus larynx preservation for T4a larynx cancer: patterns of care and survival outcomes. Int J Radiat Oncol Biol Phys. 2015 Jul 1;92(3):594-601. doi: 10.1016/j.ijrobp.2015.03.004.
  9. The Department of Veterans Affairs Laryngeal Cancer Study Group: Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991; 324:1685–90.
  10. Dietz A, Rudat V, Dreyhaupt J, Pritsch M, Hoppe F, Hagen R, Pfreundner L, Schroder U, Eckel H, Hess M, Schroder M, Schneider P, Jens B, Zenner HP, Werner JA, Engenhardt-Cabillic R, Vanselow B, Plinkert P, Niewald M, Kuhnt T, Budach W, Flentje M. Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOSI-trial). Eur Arch Otorhinolaryngol 2008; 266(8): 1291–300. Epub 2008 Oct 30.
  11. Semrau S, Haderlein M, Schmidt D, Lell M, Wolf W, Waldfahrer F, Uder M, Iro H, Kuwert T, Fietkau R. Single-cycle induction chemotherapy followed by chemoradiotherapy or surgery in patients with head and neck cancer: what are the best predictors of remission and prognosis? Cancer. 2015 Apr 15;121(8):1214-22. doi: 10.1002/cncr.29188. Epub 2014 Dec 23.
  12. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL; EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007 Oct 25;357(17):1695-704.
  13. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI; TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007 Oct 25;357(17):1705-15.
  14. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006 Feb 9;354(6):567-78.
  15. Dietz A, Flentje M, Hagen R, Bockmühl U, Kölbl O, Schilling V, Maschmeyer G, Schröder U, Sittel C, Görner M, Lenarz T, Klußmann P, Guntinas-Lichius O, Rudack C, Reinisch S, Förg T, Westhofen M, Welkoborsky HJ, Eßer D, Keilholz U (2014) Induction chemotherapy (IC) docetaxel (T), cisplatin (P), 5-fluorouracil (F) (TPF) or TP followed by concomitant boost radiotherapy (R) with or without cetuximab (E) for functional organ preservation (FOP) of resectable laryngeal and hypopharyngeal cancer(LHSCC): first results of the phase II randomized DeLOS-II study. J Clin Oncol 32(5s):6016
  16. Dietz A, Wichmann G, Flentje M, et al: Final results of the randomized phase II DeLOS-II trial: Induction chemotherapy (IC) followed by radiotherapy (R) vs. cetuximab (E) plus IC and R for functional larynx preservation in resectable laryngeal and hypopharyngeal cancer (LHSCC). J Clin Oncol 34, 2016 (suppl; abstr 6025)
  17. Dietz A, Boehm A, Horn IS, Kruber P, Bechmann I, Golusinski W, Niederwieser D, Dollner R, Remmerbach TW, Wittekind C, Dietzsch S, Hildebrandt G, Wichmann G. Assay-based response evaluation in head and neck oncology: requirements for better decision making. Eur Arch Otorhinolaryngol 2010; 267(4): 483–94. Epub 2010 Jan 6.
  18. Dietz, A. Boehm, A. Reiche, G. Mueller, P. Kruber, U. Keilholz, D. Niederwieser, G. Wichmann; Prediction of outcome of TPF with or without cetuximab induction chemotherapy in head and neck squamous cell carcinoma (HNSCC) using the FLAVINO assay. J Clin Oncol 28:15s, 2010 (suppl; abstr 5572)
  19. Wichmann G, Dietz A. Präklinische Modelle zur Etablierung innovativer Therapiestrategien: Ex?vivo?Testung der Chemo? und Immunresponse von Kopf?Hals?Tumoren [Preclinical models to establish innovative therapy strategies : Ex?vivo assessment of head and neck tumor chemo- and immune responses]. HNO. 2016 Jun 3. [Epub ahead of print]

„Nationales Zweitmeinungsnetzwerk Hodentumoren“ – eine Interimsbilanz nach 9 Jahren Laufzeit

Mark Schrader, Berlin (S. 24-26)

 

  1. Studienstatistik der Arbeitsgemeinschaft Urologische Onkologie, www.auo-online.de.
  2. Busch J, Rollig C, Weissbach L, Kempkensteffen C, Hinz S, Jahnke C, Schostak M, Lein M, Weikert S, Stephan C et al: [What is most important is what comes across : Urological guidelines from the target group's point of view]. Urologe A 2010, 49(1):75-80.
  3. Weissbach L, Bamberg M, Schmoll HJ: [Interdisciplinary consensus conference on "diagnosis and therapy of testicular tumors"]. Urologe A 1997, 36(4):362-368.
  4. Schrader M, Weissbach L, Hartmann M, Krege S, Albers P, Miller K, Heidenreich A: Burden or relief: do second-opinion centers influence the quality of care delivered to patients with testicular germ cell cancer? Eur Urol 2009, 57(5):867-872.
  5. Zengerling F, Schrader A, Mohr A, Schrader M: [National second-opinion network for testicular cancer patients. Results of a user survey]. Urologe A 2013, 52(9):1290-1295.
  6. Zengerling F, Krege S, Schrader AJ, Schrader M. National second opinion network for testicular cancer patients - transferring guidelines into practice! Aktuelle Urol. 2014 Nov;45(6):454-6. doi: 10.1055/s-0034-1395624. Epub 2014 Dec 16. German 

 

 

UPDATE: Fatigue bei Krebspatienten - Erscheinungsformen, Ursachen, Behandlung

Susanne Ditz, Heidelberg (S. 37-42)

 

  1. Cella et al. Progress toward guidelines for the management of fatigue. Oncology (Williston Park). 1998 Nov;12(11A):369-77. Review. Cella D F. Quality of life. In: Holland J (Hrsg.), Psycho-Oncology., New York: Oxford University Press, 1998:S1135–-46.
  2. Alexander et al., Evaluation of screening instruments for cancer-related fatigue syndrome in breast cancer survivors.J Clin Oncol. 2009 Mar 10;27(8):1197–1201.
  3. Minton and Stone, How common is fatigue in disease-free breast cancer survivors? A systematic review of the literature. Breast cancer Res Treat. 2008 Nov;112:5–13.
  4. Whitehead L, The measurement of fatigue in chronic illness: a systematic review of unidimensional and multidimensional fatigue measures. J Pain Symptom Manage. 2009 Jan;37(1):107–128.
  5. Singer et al., Age-and sex- standardised prevalence rates of fatigue in a large hospital-based sample of cancer patients. Br J Cancer. 2011 Jul 26;105:445-51
  6. Piper et al.; Fatigue mechanisms in cancer patients: Developing nursing theory. Oncol Nurs Forum. 1987 Nov-Dez;14(6):17–23.
  7. Horneber et al.; Cancer-related fatigue: epidemiology, pathogenesis, diagnosis and treatment Dtsch Arztebl. Int. 2012 Mar;109(9):161-72.
  8. Minton and Stone, Systematic review of the scales used for the measurement of cancer-related fatigue (CRF). AnnOncol. 2009 Jan;20(1):17–25.
  9. Kim et al. Prevalence and correlates of fatigue and depression in breast cancer survivors: Breast cancer quality care study. J Clin Oncol. 2006 Jun;24(18S):683.
  10. Heim M, und Weis J. Fatigue bei Krebserkrankung. Schattauer GmbH, Stuttgart, 2014, 205 S.
  11. Cella D F. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol.  1998 Jun;25(3 Suppl 7):43-6.
  12. Lundström and Fürst. The use of corticosteroids in Swedish palliative care. Acta Oncol. 2006;45:430–-7. Minton et al. A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst. 2008 Aug 20;100(16):1155-66 Rozans et al.  Palliative uses of methylphenidate in patients with cancer: A review. J Clin Oncol. 2002 Jan 1;20:335–339.13. 
  13. Holmes et al. Activity and Survival After Breast Cancer Diagnosis. JAMA. 2005 May 22;293:2479–2486. Wolin et al. Physical Activity and Colon Cancer Prevention: A Meta-analysis. Br J Cancer. 2009 Feb 24;100:611–616.
  14. Baumann F T, Schüle K (Hrsg.)Bewegungstherapie und Sport bei Krebs. Leitfaden für die Praxis. Deutscher Ärzteverlag, Köln. 274 S.15. 
  15. Cramp F, Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006145.16. 
  16. Rank et al.   Sporttherapie bei Krebserkrankungen. Grundlagen, Diagnostik, Praxis. Schattauer GmbH, Stuttgart, 180 S.
  17. Yates et al. Randomized Controlled Trial of an Educational Intervention for Managing Fatigue in Women Receiving Adjuvant Chemotherapy for Early-Stage Breast Cancer. J Clin Oncol 2005 Sep 1;23(25):6027–-36.
  18. Goedendorp et al. Psychosocial interventions for reducing fatigue during cancer treatment in adults.  Cochrane Database Syst Rev. 2009 Jan 21;(1).

PHARMASERVICE: Sequenztherapie des metastasierten kastrationsresistenten Prostatakarzinoms (mCRPC)

Bettina Baierl (S. 55)

 

  1. Antonarakis EA et al. J Clin Oncol 34, 2016 (suppl; abstr 5012)
  2. Maughan BL et al. J Clin Oncol 34, 2016 (suppl 2S; abstr 308)
  3. Bianchini D et al. Eur J Cancer. 2014; 50(1): 78-84
  4. Azad AA et al. Eur Urol. 2015; 67(1): 23-9
  5. Schmid SC et al. Adv Ther. 2014; 31(2): 234-41
  6. Brasso K et al. Eur Urol. 2015; 68(2): 317-24
  7. Badrising S et al. Cancer. 2014; 120(7): 968-75
  8. Badrising SK et al. The Prostate. 2016; 76(1): 32-40
  9. Caffo O et al. Eur Urol. 2015; 68: 147-53
  10. Schrader AJ et al. Eur Urol. 2014; 65(1): 30-6
  11. Cheng HH et al. Prostate Cancer Prostatic Dis. 2015; 18: 122-7
  12. Loriot Y et al. Ann Oncol. 2013; 24(7): 1807-12
  13. Noonan KL et al. Ann Oncol. 2013; 24(7): 1802-7
  14. clinicaltrials.gov (NCT02125357)
  15. Miller K et al. EAU-Kongress 2016, 11.-15.3.2016, München: Poster 775
  16. Fizazi K et al. Ann Oncol. 2016; 27(4): 699-705